-
公开(公告)号：USD964036S1
公开(公告)日：2022-09-20
申请号：US29799502
申请日：2021-07-14
申请人： Xizhong Huang
设计人： Xizhong Huang
-
公开(公告)号：US08961970B2
公开(公告)日：2015-02-24
申请号：US13799706
申请日：2013-03-13
申请人： Xizhong Huang , Malte Peters , Jennifer Lorraine Gansert , David Dong Eun Chang , Pedro Beltran , Zhu Alexander Cao
发明人： Xizhong Huang , Malte Peters , Jennifer Lorraine Gansert , David Dong Eun Chang , Pedro Beltran , Zhu Alexander Cao
IPC分类号： A61K39/395 , C07K16/28 , A61K31/4184 , A61K39/00
CPC分类号： A61K39/3955 , A61K31/4184 , A61K2039/545 , C07K16/2863 , A61K2300/00
摘要： The present invention relates to a pharmaceutical combination comprising a MEK inhibitor compound 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide or a pharmaceutically acceptable salt thereof and the IGF1R inhibitor ANTIBODY A, a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of a therapeutically effective amount of such combination to a subject in need thereof, and uses of such combination for the treatment of cancer.
摘要翻译： 本发明涉及药物组合，其包含MEK抑制剂化合物6-（4-溴-2-氟苯基氨基）-7-氟-3-甲基-3H-苯并咪唑-5-甲酸（2-羟基乙氧基） - 酰胺或 其药学上可接受的盐和IGF1R抑制剂抗体A，包含这种组合的药物组合物，用于治疗癌症的方法，包括向有需要的受试者施用治疗有效量的这种组合，以及这种组合用于治疗癌症的用途。
-
3.发明申请Combination Therapy Comprising A CDK4/6 Inhibitor and a P13K Inhibitor for Use in the Treatment of Cancer 有权包含用于治疗癌症的CDK4 / 6抑制剂和P13K抑制剂的组合疗法公开(公告)号：US20140107114A1
公开(公告)日：2014-04-17
申请号：US14124753
申请日：2012-07-02
申请人： Sunkyu Kim , Shivang Doshi , Kristy Haas , Steven Kovats , Alan Xizhong Huang , Yan Chen
发明人： Sunkyu Kim , Shivang Doshi , Kristy Haas , Steven Kovats , Alan Xizhong Huang , Yan Chen
IPC分类号： A61K31/5377 , A61K31/4439 , A61K31/519
CPC分类号： A61K31/519 , A61K31/4439 , A61K31/5377 , A61K45/06 , A61K2300/00
摘要： A combination of a CDK4/6 inhibitor and a P3Kinase inhibitor for the treatment of cancer.
摘要翻译： CDK4 / 6抑制剂与用于治疗癌症的P3Kinase抑制剂的组合。
-
公开(公告)号：US20140023661A1
公开(公告)日：2014-01-23
申请号：US13799076
申请日：2013-03-13
申请人： Xizhong Huang , Malte Dong Eun Peters , Karl Maria Schumacher , Zhu Alexander Cao , Jennifer Lorraine Gansert , David Dong Eun Chang
发明人： Xizhong Huang , Malte Dong Eun Peters , Karl Maria Schumacher , Zhu Alexander Cao , Jennifer Lorraine Gansert , David Dong Eun Chang
IPC分类号： A61K31/4439 , A61K39/395
CPC分类号： A61K31/4439 , A61K39/3955 , A61K2039/505 , C07K16/2863 , C07K2316/96 , C07K2317/565 , C07K2317/73 , C07K2317/76 , A61K2300/00
摘要： The present invention relates to a pharmaceutical combination comprising an alpha-isoform specific phosphatidylinositol 3-kinase inhibitor compound, such as (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or pharmaceutically acceptable salt thereof, and an IGF1R inhibitor (e.g., the IGF1R inhibitor ANTIBODY A, or a variant or derivative thereof), a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of therapeutically effective amounts of such inhibitors to a subject in need thereof, and uses of such combination for the treatment of cancer.
摘要翻译： 本发明涉及药物组合，其包含α-异构体特异性磷脂酰肌醇3-激酶抑制剂化合物，例如（S） - 吡咯烷-1,2-二羧酸2-酰胺1 - （{4-甲基-5- [2 - （2,2,2-三氟-1,1-二甲基 - 乙基） - 吡啶-4-基] - 噻唑-2-基} - 酰胺）或其药学上可接受的盐和IGF1R抑制剂（例如， IGF1R抑制剂抗体A或其变体或衍生物），包含这种组合的药物组合物，用于治疗癌症的方法，包括向有需要的受试者施用治疗有效量的这种抑制剂，以及这种组合用于治疗癌症的用途 。
-
公开(公告)号：US20170095463A1
公开(公告)日：2017-04-06
申请号：US15335957
申请日：2016-10-27
IPC分类号： A61K31/4439 , A61K45/06 , A61K31/436
CPC分类号： A61K31/4439 , A61K31/427 , A61K31/436 , A61K31/439 , A61K31/506 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a pharmaceutical combination comprising a phosphatidylinositol-3-kinase (PI3K) inhibitor compound which is a 2-carboxamide cycloamino urea derivative or a pharmaceutically acceptable salt thereof and at least one mammalian target of rapamycin (mTOR) inhibitor or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising such a combination; and the uses of such a combination in the treatment proliferative diseases, more specifically of mammalian target of rapamycin (mTOR) kinase dependent diseases.
-
6.发明申请2-Carboxamide Cycloamino Urea Derivatives in Combination with HSP90 Inhibitors for the Treatment of Proliferative Diseases 审中-公开2-羧酰胺环氨基脲衍生物与HSP90抑制剂联合治疗增殖性疾病公开(公告)号：US20160199365A1
公开(公告)日：2016-07-14
申请号：US15059395
申请日：2016-03-03
IPC分类号： A61K31/4439 , A61K31/519 , A61K31/52 , A61K31/5377 , A61K31/16 , A61K31/235
CPC分类号： A61K31/5377 , A61K31/16 , A61K31/235 , A61K31/428 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K31/519 , A61K31/52 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a pharmaceutical combination comprising a 2-carboxamide cycloamino urea derivative compound of formula (I) and inhibitors of Heat Shock Protein 90, and the uses of such combinations in the treatment of proliferative diseases, more specifically PI3K dependent diseases, more specifically PI3K-alpha dependent diseases.
摘要翻译： 本发明涉及包含式（I）的2-甲酰胺环氨基脲衍生物化合物和热休克蛋白90抑制剂的药物组合，以及这些组合在治疗增殖性疾病中的用途，更具体地说是PI3K依赖性疾病 特别是PI3K-α依赖性疾病。
-
公开(公告)号：US08980259B2
公开(公告)日：2015-03-17
申请号：US13799076
申请日：2013-03-13
申请人： Xizhong Huang , Malte Peters , Karl Maria Schumacher , Zhu Alexander Cao , Jennifer Lorraine Gansert , David Dong Eun Chang
发明人： Xizhong Huang , Malte Peters , Karl Maria Schumacher , Zhu Alexander Cao , Jennifer Lorraine Gansert , David Dong Eun Chang
IPC分类号： A61K31/4439 , A61K39/395 , C07K16/28 , A61K39/00
CPC分类号： A61K31/4439 , A61K39/3955 , A61K2039/505 , C07K16/2863 , C07K2316/96 , C07K2317/565 , C07K2317/73 , C07K2317/76 , A61K2300/00
摘要： The present invention relates to a pharmaceutical combination comprising an alpha-isoform specific phosphatidylinositol 3-kinase inhibitor compound, such as (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or pharmaceutically acceptable salt thereof, and an insulin-like growth factor-1 receptor (IGF1R) inhibitor (e.g., the IGF1R inhibitor ANTIBODY A, or a variant or derivative thereof), a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of therapeutically effective amounts of such inhibitors to a subject in need thereof, and uses of such combination for the treatment of cancer.
摘要翻译： 本发明涉及药物组合，其包含α-异构体特异性磷脂酰肌醇3-激酶抑制剂化合物，例如（S） - 吡咯烷-1,2-二羧酸2-酰胺1 - （{4-甲基-5- [2 - （2,2,2-三氟-1,1-二甲基 - 乙基） - 吡啶-4-基] - 噻唑-2-基} - 酰胺）或其药学上可接受的盐，以及胰岛素样生长因子 - 1受体（IGF1R）抑制剂（例如，IGF1R抑制剂抗体A或其变体或衍生物），包含这种组合的药物组合物，用于治疗癌症的方法，包括向有需要的受试者施用治疗有效量的此类抑制剂， 以及这种组合用于治疗癌症的用途。
-
8.发明申请COMPOUNDS FOR USE IN THE TREATMENT OF NEUROBLASTOMA, EWING'S SARCOMA OR RHABDOMYOSARCOMA 审中-公开用于治疗神经瘤的化合物，EWCOM的SARCOMA或RHABDOMYOSARCOMA公开(公告)号：US20150051252A1
公开(公告)日：2015-02-19
申请号：US14387636
申请日：2013-03-28
申请人： Xizhong Huang
发明人： Xizhong Huang
IPC分类号： A61K31/4439
CPC分类号： A61K31/4439 , A61K31/427 , A61K31/497 , A61K31/506
摘要： The present invention relates to a method of treating cancer selected from the group consisting of neuroblastoma, Ewing's Sarcoma, or rhabdomyosarcoma comprising administering a therapeutically effective amount of a compound of formula (I), as defined herein, or a pharmaceutically acceptable salt thereof to a subject, preferably a human, in need thereof; to use of the compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for use in the treatment of cancer selected from the group consisting of neuroblastoma, Ewing's Sarcoma, or rhabdomyosarcoma; and to use of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the treatment of cancer selected from the group consisting of neuroblastoma, Ewing's Sarcoma, or rhabdomyosarcoma.
摘要翻译： 本发明涉及一种治疗选自神经母细胞瘤，尤因氏肉瘤或横纹肌肉瘤的癌症的方法，包括将治疗有效量的本文定义的式（I）化合物或其药学上可接受的盐给予 受试者，优选人;有需要的人; 使用式（I）化合物或其药学上可接受的盐来制备用于治疗选自神经母细胞瘤，尤因氏肉瘤或横纹肌肉瘤的癌症的药物组合物; 以及使用式（I）化合物或其药学上可接受的盐在治疗选自神经母细胞瘤，尤因氏肉瘤或横纹肌肉瘤的癌症中的用途。
-
9.发明申请公开(公告)号：US20160151344A1
公开(公告)日：2016-06-02
申请号：US15018287
申请日：2016-02-08
申请人： Xizhong Huang
发明人： Xizhong Huang
IPC分类号： A61K31/4439
CPC分类号： A61K31/4439 , A61K31/427 , A61K31/497 , A61K31/506
摘要： The present invention relates to a method of treating cancer selected from the group consisting of neuroblastoma, Ewing's Sarcoma, or rhabdomyosarcoma comprising administering a therapeutically effective amount of a compound of formula (I), as defined herein, or a pharmaceutically acceptable salt thereof to a subject, preferably a human, in need thereof; to use of the compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for use in the treatment of cancer selected from the group consisting of neuroblastoma, Ewing's Sarcoma, or rhabdomyosarcoma; and to use of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the treatment of cancer selected from the group consisting of neuroblastoma, Ewing's Sarcoma, or rhabdomyosarcoma.
-
10.发明授权Combination therapy comprising a CDK4/6 inhibitor and a P13K inhibitor for use in the treatment of cancer 有权包含用于治疗癌症的CDK4 / 6抑制剂和P13K抑制剂的组合疗法公开(公告)号：US09271988B2
公开(公告)日：2016-03-01
申请号：US14124753
申请日：2012-07-02
申请人： Sunkyu Kim , Shivang Doshi , Kristy Haas , Steven Kovats , Alan Xizhong Huang , Yan Chen
发明人： Sunkyu Kim , Shivang Doshi , Kristy Haas , Steven Kovats , Alan Xizhong Huang , Yan Chen
IPC分类号： A61K31/519 , A61K31/5377 , C07D487/02 , A61K31/4439 , A61K45/06
CPC分类号： A61K31/519 , A61K31/4439 , A61K31/5377 , A61K45/06 , A61K2300/00
摘要： A combination of a CDK4/6 inhibitor and a P3Kinase inhibitor for the treatment of cancer.
摘要翻译： CDK4 / 6抑制剂与用于治疗癌症的P3Kinase抑制剂的组合。
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.032 秒)